Dihydroergotamine Nasal Spray [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2019-06-26 10:47 (617 d 16:50 ago) – Posting: # 20363
Views: 1,836

Hi all,


» » If it is required, …
»
» It is. If you would deviate from a guidance without a controlled correspondence you risk an RtR.

It would be an interesting lawsuit, if the company gets an RtR for lack of baseline correction and sues the FDA because the formal requirement is meaningless.
Perhaps a case where FDA could hide behind the fact that it is a draft and contains nonbinding recommendations blahblah?

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,366 posts in 4,462 threads, 1,493 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Friday 03:38 UTC (Europe/Vienna)

The statistician has no magic touch by which
he may come in at the stage of tabulation
and make something of nothing.    W. Edwards Deming

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5